HR Execs on the Move

Prilenia

www.prilenia.com

 
We are a clinical stage biotech startup, led by Michael Hayden, MD, PhD., together with a highly experienced team with a track record of success. Michael is the founder of five biotech companies and was previously President of Global R&D and Chief Scientific Officer at Teva. He has directed the development of multiple innovative drug products leading to 35 approvals between 2012-2018.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details
Michael Hayden
Chief Executive Officer Profile

Similar Companies

CaptureRx

Founded in 2000, San Antonio-based CaptureRx is a healthcare technology company and leading 340B solution provider that puts people first, touching millions of patient lives through customer obsession and innovative products and services that support relationships among payers, providers, pharmacies and patients. Our solutions manage inventory and financial flow for 340B prescriptions filled at contract pharmacies and perform the eligibility checks required to comply with 340B program requirements. Using a process that`s seamless to the covered entity, pharmacy and patient, our Cumulus platform has processed more than 190 million patient encounters and more than 750 million switch claims. Currently, CaptureRx solutions serve more than 500 hospitals and health centers in 45 states via a robust pharmacy network of more than 3,500 contracted locations of independent, national and regional pharmacies.

Lipo Chemicals

Lipo Chemicals is a Paterson, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Oncology Therapeutics Network

Oncology Therapeutics Network is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Colucid

CoLucid was founded in 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatments for CNS disorders. The company`s investors include Pappas Ventures, Domain Associates, Care Capital, Novo Ventures, Triathalon Medical Ventures, TVM Life Science Management, Auriga Partners and Pearl Street Venture Funds. The company is developing oral lasmiditan for the treatment of migraine headache and intravenous lasmiditan for treatment of headache pain by health care professionals.